论文部分内容阅读
目的探讨诺和锐30与诺和灵30R治疗初诊2型糖尿病患者的临床疗效及安全性。方法选取2013年6月—2014年12月成都市新都区人民医院收治的初诊2型糖尿病患者100例,按随机数字表法将其分为Ⅰ组与Ⅱ组,各50例。Ⅰ组患者于早晚餐前皮下注射诺和锐30治疗,Ⅱ组患者于早晚餐前皮下注射诺和灵30R治疗。观察两组患者治疗前后糖化血红蛋白(Hb A1c)、空腹血糖(FPG)、餐后2h血糖(2h PG)水平及低血糖发生情况。结果治疗前两组患者Hb A1c、FPG、2h PG水平比较,差异无统计学意义(P>0.05);治疗后Ⅰ组患者2h PG水平低于Ⅱ组,低血糖发生率低于Ⅱ组,差异有统计学意义(P<0.05)。结论诺和锐30治疗初诊2型糖尿病患者的临床疗效显著,可降低患者低血糖的发生风险。
Objective To investigate the clinical efficacy and safety of Novo-Rui 30 and Novo-30R in the treatment of newly diagnosed type 2 diabetic patients. Methods A total of 100 newly diagnosed type 2 diabetic patients admitted to the People ’s Hospital of Xindu District, Chengdu from June 2013 to December 2014 were selected and randomly divided into group Ⅰ and group Ⅱ, 50 cases in each group. Patients in group Ⅰ were treated with Novolin 30 subcutaneously before breakfast and dinner, and those in group Ⅱ were given subcutaneous injection of Novolin 30R before and after dinner. The levels of Hb A1c, fasting blood glucose (FPG), 2h postprandial blood glucose (2h PG) and hypoglycemia in both groups were observed before and after treatment. Results There was no significant difference in Hb A1c, FPG, 2h PG levels between the two groups before treatment (P> 0.05). After treatment, the level of PG in group I was lower than that in group II and the incidence of hypoglycemia was lower than that in group II There was statistical significance (P <0.05). Conclusion Novo-Rui 30 treatment of newly diagnosed type 2 diabetes patients with significant clinical efficacy, reduce the risk of hypoglycemia in patients.